Vir Biotechnology, Inc. (VIR)

10,39 +1,21 (+13,18%) Alla chiusura: 04:00PM EDT

Vir Biotechnology, Inc.

1800 Owens Street
Suite 900
San Francisco, CA 94158
United States
415 906 4324
https://www.vir.bio

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 587

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.	CEO & Director	4,47M	N/D	1969
Mr. Sung H. Lee	Executive VP & CFO	968,45k	N/D	1970
Dr. Ann M. Hanly Ph.D.	Executive VP & Chief Technology Officer	896,07k	N/D	1970
Dr. Jeff Calcagno M.D.	Executive VP & Chief Business Officer	860,49k	N/D	1961
Dr. Klaus Frueh Ph.D.	Co-Founder & Scientific Advisor	177,66k	N/D	1960
Dr. Lawrence Corey M.D.	Co-Founder & Scientific Advisor	N/D	N/D	1948
Dr. Louis J. Picker M.D.	Co-Founder & Scientific Advisor	N/D	N/D	N/D
Dr. Jennifer Eileen Towne Ph.D.	Executive VP & Chief Scientific Officer	N/D	N/D	N/D
Ms. Heather Rowe Armstrong	Vice President of Investor Relations	N/D	N/D	N/D
Ms. Vanina De Verneuil J.D.	Executive VP, General Counsel & Corporate Secretary	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Governance aziendale

L'ISS Governance QualityScore di Vir Biotechnology, Inc. al 1 maggio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 4; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.